2026.10.05The 2026 Chang Gung Medical Week international medical conference invited Dr. Chung-Ling Liang, MD, PhD, Chief Medical Officer of SUNHAWK VISION BIO, to deliver a lecture sharing the latest research and development of novel drugs and emerging therapeutic trends for myopia control and dry eye disease.
2026.09.17SUNHAWKVISION Expands Core Technology Platform to Prevent and Treat Ocular Toxicities Induced by ADC Anticancer Drugs, Filing U.S. Patent to Secure Global Strategic IP Position
2026.09.07The Phase II clinical trial of myopia control treatment has enrolled a total of 112 participants. Approximately 80% of the subjects have successfully completed one year of the trial. The last subject is expected to complete the study medication administration by December 31, 2026, marking the completion of the treatment phase. The trial is progressing smoothly and in line with expectations.
2026.06.11Sunhawk Vision Mandated by Global Mega-Pharma Titans for Exclusive One-on-One Closed-Door Summits at BIO 2026 to Leverage Strategic Licensing and Equity Bids for SHJ002 Platform.
2026.05.29The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of May 29, 50% subjects of this trial has successfully completed the one-year treatment protocol and the remaining 50% subjects are scheduled to complete all treatment by December 2026. The study is scheduled for unblinding in the first quarter of 2027.
2026.04.28Sunhawk Vision Announces SHJ002 Phase 2 DED Results in NIH-Indexed Clinical Therapeutics: Breakthrough Efficacy in Corneal Repair to Redefine Global Market Landscape
2026.04.22The Company Signs Strategic Licensing Partnership Agreement for SHJ002 with a Renowned Global Consultancy.
2026.04.02The Phase II clinical trial of myopia control treatment has enrolled a total of 140 participants across sites in the United States and Taiwan. As of April 2, 25 subjects have successfully completed the one-year treatment protocol. The study is scheduled for unblinding in the first quarter of 2027.
2026.03.16The company has successfully completed the interim review by the Data Monitoring Committee (DMC) for its Phase II clinical trial of childhood myopia treatment.
2025.12.31Enrollment of phase-2 myopia control trial (NCT06579287) of Sunhawk vision had successfully completed on December 31, 2025.
2025.12.10Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).
2025.11.03Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.
2025.10.07The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.
2025.09.22Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).
2025.07.29Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.
2025.05.20Preliminary results of Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome
2025.05.06The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.
2025.04.15Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.
